Cetuximab in non-small-cell lung cancer.

Authors:
Address: Medical Oncology Unit, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
Journal:

Publication:

abstract

Cetuximab is a chimeric human-mouse anti-EGF receptor monoclonal antibody. In Phase I studies, no dose-limiting toxicities were observed with cetuximab as a single agent or combined with chemotherapy; pharmacokinetic and pharmacodynamic analyses supported 250 mg/m(2) weekly administration. Skin toxicity, diarrhea and fatigue were the most common toxicities. The positive results obtained in Phase II trials in patients with advanced non-small-cell lung cancer prompted two randomized Phase III trials evaluating cetuximab in addition to first-line chemotherapy. Both trials showed a small benefit in overall survival for the experimental treatment, which was considered insufficient by the EMA for marketing approval. However, a subgroup analysis of the FLEX Phase III trial recently demonstrated a larger survival benefit from the experimental treatment in patients with high immunohistochemical EGF receptor expression. This finding, if confirmed prospectively, could represent a new opportunity for positioning cetuximab into the standard treatment of advanced non-small-cell lung carcinoma.

Related Articles
Review Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Drugs Today (Barc). 2005
Review Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J, Burtness B. Drugs Today (Barc). 2005 Feb; 41(2):107-27.
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Curr Oncol. 2010
Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R, Head and Neck Cancer Disease Site Group. Curr Oncol. 2010 Jun; 17(3):37-48.
Review Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Drugs. 2003
Review Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL, Figgitt DP. Drugs. 2003; 63(8):803-43.
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Lancet. 2009
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, et al. Lancet. 2009 May 2; 373(9674):1525-31.
Review Integration of novel agents in the treatment of colorectal cancer.
Cancer Chemother Pharmacol. 2004
Review Integration of novel agents in the treatment of colorectal cancer.
Iqbal S, Lenz HJ. Cancer Chemother Pharmacol. 2004 Sep; 54 Suppl 1:S32-9.

To top • Home

TraveldoctorOnline 2001 • Disclaimer • webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.